40
Participants
Start Date
December 11, 2023
Primary Completion Date
October 2, 2026
Study Completion Date
October 2, 2026
Inavolisib
Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.
Atezolizumab
Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
RECRUITING
Vanderbilt-Ingram Cancer Ctr, Nashville
WITHDRAWN
California Cancer Associates for Research & Excellence, Inc., San Marcos
RECRUITING
Moores Cancer Center at UC San Diego Health, La Jolla
RECRUITING
BC Cancer Vancouver Centre, Vancouver
RECRUITING
Princess Margaret Cancer Center, Toronto
RECRUITING
Jewish General Hospital, Montreal
WITHDRAWN
Seoul National University Hospital, Seoul
RECRUITING
Samsung Medical Center, Seoul
Hoffmann-La Roche
INDUSTRY